Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ST-01156 · 1 trial · 4 indications
To characterize the safety, tolerability, and adverse event (AE) profile of escalating doses of ST-01156 administered for 5 consecutive days followed by 2 days without study drug administration every 7 days, with a cycle defined as 28 days (4 weeks).
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ST-01156, administered orally once daily for 5 consecutive days followed by 2 days without study drug administration every 7 days |
| Name | Type | Description |
|---|---|---|
| ST-01156 | DRUG | ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer |
Inclusion Criteria: * Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old. * Has a metastatic or locally advanced an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ST-01156 is an investigational small molecule drug being developed by BeyondSpring, Inc. for advanced solid tumors. It is in Phase 1 clinical development and is described as an RBM39 degrader. It has not been approved by the FDA and remains under study in a single recruiting trial.
ST-01156 is being studied for the treatment of advanced solid malignancies. The Phase 1/1B trial enrolling patients lists advanced solid tumors, Ewing sarcoma, hepatocellular carcinoma (HCC), and biliary tract cancer (BTC) as the conditions under investigation. It is investigational and not approved for any use.
ST-01156 targets RBM39, an RNA-binding protein, and is characterized as a small molecule RBM39 degrader. By degrading RBM39, the drug is designed to interfere with the splicing and transcriptional processes that tumor cells depend on. This mechanism is being evaluated in patients with advanced solid malignancies.
BeyondSpring, Inc. (ticker BYSI) is developing ST-01156. The company is the sponsor of the Phase 1/1B study of the drug in advanced solid malignancies. BeyondSpring is a biopharmaceutical company focused on oncology therapeutics.
ST-01156 is in Phase 1 clinical development. The ongoing study is a Phase 1/1B trial, and the drug is investigational, meaning it has not been approved by the FDA. No trials of ST-01156 have been completed to date.
ST-01156 is being evaluated in one clinical trial, NCT07197554, titled a Phase 1/1B study of ST-01156, a small molecule RBM39 degrader, in patients with advanced solid malignancies. The trial is currently recruiting in the United States and has an planned enrollment of 171 participants.